Changes in expression of oncogenes and TP53 tumour suppressor gene as biomarkers in head and neck cancers

被引:0
作者
István Szanyi
Miklós Bauer
Imre Gerlinger
Tamás Járai
Gyula Gőbel
László Lujber
Éva Szabadi
Katalin Fehér
Ágoston Ember
István Ember
István Kiss
机构
[1] Pécs University,Faculty of Medicine, Department of Otolaryngology Head and Neck Surgery
[2] Pécs University,Faculty of Medicine, Department of Public Health
[3] Pécs University,Faculty of Medicine, Department of Surgery
来源
European Archives of Oto-Rhino-Laryngology | 2011年 / 268卷
关键词
Oncogene and tumour suppressor gene expression; Biomarker; Prevention; Head and neck cancer;
D O I
暂无
中图分类号
学科分类号
摘要
Despite modern diagnostic procedures and up-to-date therapy, the survival of head and neck tumour patients is unfavourable. This can be explained by several factors, one of which is the late recognition of the tumour. This study related to the changes in expression of the c-myc and Ha-ras oncogenes and the p53 tumour suppressor gene as biomarkers in head and neck cancer cases. The gene expressions were investigated on RNA gained from peripheral white blood cells of head and neck cancers patients before and after definitive treatment. The results were compared with those on a control group of patients with non-tumorous diseases. The gene expressions were significantly higher in the cancer group than that in the control group (volunteer medical staff and medical students). After definitive treatment, the expressions of all these genes were decreased in patients in whom there was no recurrence of the tumour, but enhanced in the event of recurrence. Such measurement may serve as reliable biomarkers to monitor tumour development and the efficiency of therapy. The method may also be useful for the early identification of populations exposed to noxe, which may lead to the development of head and neck cancers.
引用
收藏
页码:1041 / 1046
页数:5
相关论文
共 164 条
[1]  
Ottó Sz(2007)Morbidity and mortality of the malignant tumours. [in Hungarian] Motesz magazin 2 14-21
[2]  
Kásler M(2003)Prevention, early recognition and therapy of the oral cavity, pharyngeal and laryngeal tumours. [in Hungarian] Orvostovábbképző Szemle 10 13-17
[3]  
Élő J(1992)Trends of cancer mortality in Europe 1955–1989 Eur J Cancer 28 132-245
[4]  
Gyenes M(1998)Oncogene and suppressor gene expression as a biomarker for ethylene oxide exposure Cancer Detect Prev 22 241-218
[5]  
Vecchia CL(1999)Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features Oncogene 18 211-515
[6]  
Lucchini F(1991)Analysis of gene amplification in head-and-neck squamous cell carcinoma Int J Cancer 48 511-131
[7]  
Negri E(1997)Investigation of c-myc and K-ras amplification in renal clear cell adenocarcinoma Cancer Lett 111 127-1152
[8]  
Bojler P(1998)Effect of ABVD therapeutic protocol on oncogene and tumour suppressor gene expression in CBA/CA mice Anticancer Res 18 1149-4930
[9]  
Maisonnevre P(2000)P53 mutation in smears of oral squamous carcinoma Anticancer Res 20 4927-600
[10]  
Levi F(2002)P53, mdm2 and p21 expression in oral sqamous cell carcinomas: relationship with clinicopathologic factors Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94 593-2116